Intranasal etripamil safe, effective for conversion of Paroxysmal supraventricular tachycardia to sinus rhythm
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301) | Circulation: Arrhythmia and Electrophysiology
Nasal Spray for Stopping PSVT Seems Feasible, Safe in Long Term
PDF) Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia
NODE-302 Data Supports Etripamil Nasal Spray for PSVT Resolution
A Nasal Spray for Rapid Heartbeat Disorder Could Be Best Option for Self-Treatment, Study Shows
Self-Administered Etripamil Safe, Effective for Paroxysmal Supraventricular Tachycardia | Health | republic-online.com
Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm | Journal of the American College of Cardiology
Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm | Journal of the American College of Cardiology
Snortable drug that mends irregular heartbeat within 30 minutes could be rolled out next year | Daily Mail Online
The role of self-administered intranasal etripamil in the management of SVT: the RAPID trial – BCS Heartbeat
RAPID return to sinus rhythm after SVT using intranasal etripamil | Nature Reviews Cardiology
Etripamil Continues to Show Promise in Paroxysmal SVT: NODE-302 | tctmd.com
Nasal spray shows potential for quickly treating arrhythmia
NODE clinical trials of Etripamil nasal spray for PSVT – All About Cardiovascular System and Disorders
Etripamil Nasal Spray shows positive topline results in Paroxysmal Supraventricular Tachycardia
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301) | Circulation: Arrhythmia and Electrophysiology
A Nasal Spray for Rapid Heartbeat Disorder Could Be Best Option for Self-Treatment, Study Shows
First Nasal Spray Successfully Treats Supraventricular Tachycardia | DAIC
Milestone Pharmaceuticals' etripamil nasal spray meets primary endpoint of phase 3 trial in PSVT
Etripamil | PDF
Etripamil - Our Research & Dev - Milestone Pharma
StudyPages - Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia
Etripamil Nasal Spray For Acute Termination Of Spontaneous Episodes Of Paroxysmal Supraventricular Tachycardia. NODE-301 Trial
